文献速递乳腺癌胸部肿瘤消化系统肿瘤

补充医学与可治愈癌症患者拒绝常规治疗及生存的关联

Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers.
PubMed 文献 · JAMA Oncol · 2018-01-01

结论提示CM相关死亡风险可能由拒绝常规治疗介导。

要点

  • 接受CM的可治愈癌症患者拒绝手术、化疗、放疗和激素治疗的比例显著高于对照组。
  • CM与死亡风险独立相关(HR=2.08,95%CI 1.50-2.90),但纳入治疗拒绝后关联不显著。

核心结论

  • 接受补充医学的可治愈癌症患者更可能拒绝常规癌症治疗,且死亡风险更高。
  • 补充医学相关的死亡风险可能由拒绝常规治疗所介导。

研究设计与样本

  • 匹配变量包括年龄、临床分期、Charlson-Deyo合并症评分、保险类型、种族/民族、诊断年份和癌症类型。

主要发现

  • CM组与对照组在开始常规治疗延迟方面无差异。
  • CM组拒绝手术率7.0%(18/258) vs 0.1%(1/1031),P<.001。
  • CM组拒绝化疗率34.1%(88/258) vs 3.2%(33/1032),P<.001。
  • CM组拒绝放疗率53.0%(106/200) vs 2.3%(16/711),P<.001。
  • CM组拒绝激素治疗率33.7%(87/258) vs 2.8%(29/1032),P<.001。

临床怎么用

  • 肿瘤内科医生应关注患者使用补充医学的情况,并评估其是否可能影响常规治疗决策。
  • 对使用补充医学的患者,应加强沟通,强调常规治疗(手术、化疗、放疗、激素治疗)对可治愈癌症的生存获益。
  • 需警惕补充医学使用者拒绝常规治疗的风险,及时干预以改善治疗依从性。

局限性

  • 本研究为回顾性观察性研究,可能存在未测量的混杂因素。
  • 补充医学组样本量较小(258例),匹配后对照组1032例,统计效能有限。
  • 补充医学的定义基于数据库编码,可能无法全面反映补充医学的实际使用情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There is limited information on the association among complementary medicine (CM), adherence to conventional cancer treatment (CCT), and overall survival of patients with cancer who receive CM compared with those who do not receive CM. OBJECTIVES: To compare overall survival between patients with cancer receiving CCT with or without CM and to compare adherence to treatment and characteristics of patients receiving CCT with or without CM. DESIGN, SETTING, AND PARTICIPANTS: This retrospective observational study used data from the National Cancer Database on 1 901 815 patients from 1500 Commission on Cancer-accredited centers across the United States who were diagnosed with nonmetastatic breast, prostate, lung, or colorectal cancer between January 1, 2004, and December 31, 2013. Patients were matched on age, clinical group stage, Charlson-Deyo comorbidity score, insurance type, race/ethnicity, year of diagnosis, and cancer type. Statistical analysis was conducted from November 8, 2017, to April 9, 2018. EXPOSURES: Use of CM was defined as "Other-Unproven: Cancer treatments administered by nonmedical personnel" in addition to at least 1 CCT modality, defined as surgery, radiotherapy, chemotherapy, and/or hormone therapy. MAIN OUTCOMES AND MEASURES: Overall survival, adherence to treatment, and patient characteristics. RESULTS: The entire cohort comprised 1 901 815 patients with cancer (258 patients in the CM group and 1 901 557 patients in the control group). In the main analyses following matching, 258 patients (199 women and 59 men; mean age, 56 years [interquartile range, 48-64 years]) were in the CM group, and 1032 patients (798 women and 234 men; mean age, 56 years [interquartile range, 48-64 years]) were in the control group. Patients who chose CM did not have a longer delay to initiation of CCT but had higher refusal rates of surgery (7.0% [18 of 258] vs 0.1% [1 of 1031]; P < .001), chemotherapy (34.1% [88 of 258] vs 3.2% [33 of 1032]; P < .001), radiotherapy (53.0% [106 of 200] vs 2.3% [16 of 711]; P < .001), and hormone therapy (33.7% [87 of 258] vs 2.8% [29 of 1032]; P < .001). Use of CM was associated with poorer 5-year overall survival compared with no CM (82.2% [95% CI, 76.0%-87.0%] vs 86.6% [95% CI, 84.0%-88.9%]; P = .001) and was independently associated with greater risk of death (hazard ratio, 2.08; 95% CI, 1.50-2.90) in a multivariate model that did not include treatment delay or refusal. However, there was no significant association between CM and survival once treatment delay or refusal was included in the model (hazard ratio, 1.39; 95% CI, 0.83-2.33). CONCLUSIONS AND RELEVANCE: In this study, patients who received CM were more likely to refuse additional CCT, and had a higher risk of death. The results suggest that mortality risk associated with CM was mediated by the refusal of CCT.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Johnson SB, Park HS, Gross CP, et al. Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers. JAMA Oncol. 2018. PMID: 30027204. doi:10.1001/jamaoncol.2018.2487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。